Abstract
A typical feature of ageing is a chronic, low-grade inflammation characterized by a general increase in the production of proinflammatory cytokines and inflammatory markers (“inflamm-ageing”). This status may slowly damage one or several organs, especially when unfavorable genetic polymorphisms and epigenetic alterations are concomitant, leading to an increased risk of frailty together with the onset of age-related chronic diseases. The contribution of different tissues (adipose tissue, muscle), organs (brain, liver), immune system and ecosystems (gut microbiota) to age-related inflammation (“inflamm-ageing”) will be discussed in this review in the context of its onset/progression leading to site-restricted and systemic effects. Moreover, some of the possible strategies and therapies to counteract the different sources of molecular mediators which lead to the age-related inflammatory phenotype will be presented.
Keywords: Ageing, age-related diseases, immunosenescence, inflammation
Current Pharmaceutical Design
Title: Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Volume: 16 Issue: 6
Author(s): E. Cevenini, C. Caruso, G. Candore, M. Capri, D. Nuzzo, G. Duro, C. Rizzo, G. Colonna-Romano, D. Lio, D. Di Carlo, M. G. Palmas, M. Scurti, E. Pini, C. Franceschi and S. Vasto
Affiliation:
Keywords: Ageing, age-related diseases, immunosenescence, inflammation
Abstract: A typical feature of ageing is a chronic, low-grade inflammation characterized by a general increase in the production of proinflammatory cytokines and inflammatory markers (“inflamm-ageing”). This status may slowly damage one or several organs, especially when unfavorable genetic polymorphisms and epigenetic alterations are concomitant, leading to an increased risk of frailty together with the onset of age-related chronic diseases. The contribution of different tissues (adipose tissue, muscle), organs (brain, liver), immune system and ecosystems (gut microbiota) to age-related inflammation (“inflamm-ageing”) will be discussed in this review in the context of its onset/progression leading to site-restricted and systemic effects. Moreover, some of the possible strategies and therapies to counteract the different sources of molecular mediators which lead to the age-related inflammatory phenotype will be presented.
Export Options
About this article
Cite this article as:
Cevenini E., Caruso C., Candore G., Capri M., Nuzzo D., Duro G., Rizzo C., Colonna-Romano G., Lio D., Carlo Di D., Palmas G. M., Scurti M., Pini E., Franceschi C. and Vasto S., Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches, Current Pharmaceutical Design 2010; 16 (6) . https://dx.doi.org/10.2174/138161210790883840
DOI https://dx.doi.org/10.2174/138161210790883840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Potential of Cell-Internalizing Aptamers
Current Topics in Medicinal Chemistry Substitution at Phenyl Rings of Chalcone and Schiff Base Moieties Accounts for their Antiproliferative Activity
Anti-Cancer Agents in Medicinal Chemistry Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry EDITORIAL
Current Signal Transduction Therapy Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry O-6-methylguanine-DNA Methyltransferase Inhibits Gastric Carcinoma Cell Migration and Invasion by Downregulation of Matrix Metalloproteinase 2
Anti-Cancer Agents in Medicinal Chemistry S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast
Current Cancer Drug Targets Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients
Drug Metabolism Letters Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Synthesis of Mannich Bases by Two Different Methods and Evaluation of their Acetylcholine Esterase and Carbonic Anhydrase Inhibitory Activities
Letters in Drug Design & Discovery Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Epigenetic Mechanisms Underlying Diet-Sourced Compounds in the Prevention and Treatment of Gastrointestinal Cancer
Anti-Cancer Agents in Medicinal Chemistry In Vitro Evaluation of Antimicrobial and Antiproliferative Activities for Compounds Isolated from the Ficus Bubu Warb. (Moraceae) Fruits: Chemotaxonomic Significance
Drug Delivery Letters Anti-Oxidants as Chemopreventive Agents in Prostate Cancer: A Gap Between Preclinical and Clinical Studies
Recent Patents on Anti-Cancer Drug Discovery MK-FSVM-SVDD: A Multiple Kernel-based Fuzzy SVM Model for Predicting DNA-binding Proteins via Support Vector Data Description
Current Bioinformatics